{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-004373","form_type":"8-K","ticker":"NTRB","cik":"0001676047","company_name":"NutriBand Inc.","filed_at":"2022-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.765456+00:00","generated_at":"2026-06-27T13:37:43.262007+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nutriband receives US patent for AVERSA abuse deterrent transdermal technology","bullets":["USPTO issued patent for 'Abuse and Misuse Deterrent Transdermal System' covering AVERSA platform.","Lead product AVERSA Fentanyl could be first abuse deterrent fentanyl transdermal system.","Expanded pipeline includes AVERSA buprenorphine and AVERSA methylphenidate.","Patents also granted in Europe, Japan, Korea, Russia, Mexico, Australia.","CEO Gareth Sheridan calls it an important milestone for Nutriband."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-004373","json":"https://secwatch.observer/filing/0001213900-22-004373.json","markdown":"https://secwatch.observer/filing/0001213900-22-004373.md","text":"https://secwatch.observer/filing/0001213900-22-004373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676047/000121390022004373/0001213900-22-004373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676047/000121390022004373/ea154687-8k_nutriband.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:37:43.262007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}